1,695 results on '"Neelapu, Sattva S"'
Search Results
2. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy
3. List of Contributors
4. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial
5. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial
6. PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma
7. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium
8. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
9. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
10. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
11. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
12. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy
13. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease
14. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
15. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
16. A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
17. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
18. Mechanisms of Resistance and Relapse After CAR-T Cell Therapy
19. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma
20. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
21. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights
22. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
23. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma
24. SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
25. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
26. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
27. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
28. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
29. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
30. Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
31. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
32. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
33. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
34. The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy
35. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy
36. Analysis of Colonic FDG Uptake and Association with Response and Toxicity to CART in LBCL Patients
37. Clinical Factors Associated with Failure to Manufacture Commercial CAR-T Cell Products Among LBCL Patients
38. The Microenvironment in Follicular Lymphoma
39. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
40. CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity
41. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
42. CAR Treg cells: prime suspects in therapeutic resistance
43. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
44. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
45. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
46. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma
47. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities
48. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
49. A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed/refractory follicular lymphoma
50. Role of the tumor microenvironment in mature B-cell lymphoid malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.